6 How does the method change what we measure? Comparing virtual reality and text-based surveys for the assessment of moral decisions in traffic dilemmas.

7 Inter-individual genomic heterogeneity within European population isolates.

8 Comparative genomics of a subset of Adherent/Invasive Escherichia coli strains isolated from individuals without inflammatory bowel disease.

9 Proteomic dataset: Profiling of membrane fraction of isolated from Crohn's disease patients after adhesion and invasion experiments.

10 Inflammation associated ethanolamine facilitates infection by Crohn's disease-linked adherent-invasive Escherichia coli.

11 Characteristics and pathogenic role of adherent-invasive Escherichia coli in inflammatory bowel disease: Potential impact on clinical outcomes.

12 The Unique Lifestyle of Crohn's Disease-Associated Adherent-Invasive Escherichia coli.

13 Ileocecal thickening: Clinical approach to a common problem.

14 Critical success factors for the implementation and adoption of e-learning for junior health care workers in Dadaab refugee camp Kenya.

15 multidrug resistance 1 gene polymorphisms may determine crohn's disease behavior in patients from rio de janeiro

16 qualidade de vida de pacientes portadores de doença inflamatória intestinal calidad de vida de pacientes portadores de enfermedad inflamatoria intestinal quality of life of patients with inflammatory bowel disease

17 drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

18 ¿cuándo es demasiado pronto y cuándo demasiado tarde para la cirugía en la enfermedad de crohn? when is it too early or too late for surgery in crohn's disease?

19 use of anorectal ultrasounds in perianal crohn's disease: consistency with clinical data utilidad de la ecografía anorrectal en el crohn perianal y su concordancia con la clínica

20 the role of the innate immune system in granulomatous disorders

21 drugs as causative agents and therapeutic agents in inflammatory bowel disease

22 Diagnosis of ulcerative colitis and Crohn's disease using transabdominal ultrasonography.

23 Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort.

24 Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease.

25 RELATIONSHIP AMONG PSYCHOLOGICAL WELL-BEING, RESILIENCE AND COPING WITH SOCIAL AND CLINICAL FEATURES IN CROHN'S DISEASE PATIENTS.

26 Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review.

27 Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes?

28 Quality of life and colorectal function in Crohn's disease patients that underwent ileocecal resection during childhood.

29 Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease.

30 The Impact of Anti-Tumor Necrosis Factor Alpha Therapy on Postoperative Complications in Pediatric Crohn's Disease.

31 A novel surgical predictive model for Chinese Crohn's disease patients.

32 Role of environmental factors in the pathogenesis of Crohn's disease: a critical review.

33 Early Surgery Versus Biologic Therapy in Limited Nonstricturing Ileocecal Crohn's Disease-A Decision-making Analysis.

34 Growth Control of Adherent-Invasive (AIEC) by the Predator Bacteria : A New Therapeutic Approach for Crohn's Disease Patients.

35 The Crohn's disease-associated Escherichia coli strain LF82 relies on SOS and stringent responses to survive, multiply and tolerate antibiotics within macrophages.

36 Macrophages Inability to Mediate Adherent-Invasive Replication is Linked to Autophagy in Crohn's Disease Patients.

37 Enhanced E. coli LF82 translocation through follicle-associated epithelium in Crohn's disease is dependent on long polar fimbriae and CEACAM6-expression, and increases paracellular permeability.

38 The Vat-AIEC protease promotes crossing of the intestinal mucus layer by Crohn's disease-associated Escherichia coli

39 Saccharomyces cerevisiaeCNCMI-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn's disease

40 Adherent-invasive Escherichia coli (AIEC) in pediatric Crohn's disease patients: Phenotypic and genetic pathogenic features

41 Replication of Crohn's disease-associated AIEC within macrophages is dependent on TNF-α secretion

42 Molecular diversity of Escherichia coli in the human gut: New ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease

43 Regulatory and functional co-operation of flagella and type 1 pill in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn's disease

44 Metagenomics-Based, Strain-Level Analysis of Escherichia coli From a Time-Series of Microbiome Samples From a Crohn's Disease Patient

45 The Vat-AIEC protease promotes crossing of the intestinal mucus layer by Crohn's disease-associatedEscherichia coli

46 Mo1753 Epigenetic Mechanisms of AIEC-Receptor CEACAM6 Regulation in Crohn's Disease

47 Sa1808 Crohn's Disease-Associated Escherichia coli (AIEC) Invade Macrophages by Suppressing NFκB Signaling

48 Su1876 Chromatin Remodelling and Micro-RNA Signatures: Epigenetic Mechanisms of AIEC-Receptor CEACAM6 Regulation in Crohn's Disease

49 Comparative genomics of adherent-invasive Escherichia coli (AIEC) associated with Crohn's disease. O-003.

50 79 AIEC-Receptor CEACAM6 Abnormal Expression in Crohn's Disease Depends on Hypoxia Responsive Elements Methylation Status

51 Replication of Crohn's disease-associated AIEC within macrophages is dependent on TNF-α secretion

52 A Case-Based Approach to New Directions in Dietary Therapy of Crohn's Disease: Food for Thought.

53 Certolizumab pegol for induction of remission in Crohn's disease

54 Lymphocytotoxic and microbial antibodies in Crohn's disease and matched controls

55 Enteral nutritional therapy for induction of remission in Crohn's disease

56 Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial

57 Evaluation of Treatment Response in Active Crohn's disease by low-field magnetic resonance imaging

58 analysis of the factors related to anti-tnf alpha response in the treatment of crohn's disease

59 fistulazing perianal crohn's disease – update and new ongoing treatments

60 meningitis por listeria como complicación del tratamiento con infliximab en paciente con enfermedad de crohn listeria meningitis as complication of treatment with infliximab in a patient with crohn's disease

61 osteonecrosis in a patient with crohn's disease unrelated to corticosteroid use

62 crohn's disease associated with sweet's syndrome and sjögren's syndrome treated with infliximab

63 antineutrophil cytoplasmic antibodies associated vasculitis in patient with crohn's disease treated with adalimumab

64 crohn's disease: upper gastrointestinal involvement

65 oral 5-aminosalicyclic acid versus 6-methylprednisolone in active crohn's disease

66 computed tomography enterography and magnetic resonance enterography in small intestine of crohn's disease

67 canadian association of gastroenterology clinical practice guidelines: the use of infliximab in crohn's disease

68 Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life

69 Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

70 Adalimumab induces deep remission in patients with Crohn's disease

71 Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease

72 A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

73 Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease

74 Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

75 Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response

76 Endogenous Antibody Production to Botulinum Toxin in an Adult with Intestinal Colonization Botulism and Underlying Crohn's Disease

77 Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease

78 Pathogens in Crohn's Disease: The Role of Adherent Invasive Escherichia coli.

79 Validation of a Model Estimating the Budget Impact of Video Capsule Endoscopy for Surveillance of Crohn's Disease in an Italian Center.

80 TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn's disease.

Keyword Connections

Journals

Research Groups

Bibliographies